Alpha Cognition (ACOG) vs Alector (ALEC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Alector (ALEC) over the past year, gaining 17.1% versus a loss of 34.4%. Alector is the larger company by market cap ($228.3 million vs $197.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | ALEC |
|---|---|---|
| Share price | $9.06 | $2.05 |
| Market cap | $197.31M | $228.34M |
| 1-day change | +0.22% | +1.24% |
| YTD return | +39.08% | +29.49% |
| 1-year return | +17.10% | -34.42% |
| 5-year return | — | -91.33% |
| EPS (TTM) | $-1.32 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $3.40 |
| 52-week low | $4.50 | $1.09 |
| Distance from 52-week high | -10.65% | -39.85% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +98.68% | +61.37% |
| Average volume | 125.72K | 2.86M |
| Shares outstanding | 21.78M | 111.66M |
| Employees | 71 | 103 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed ALEC by 51.5 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Alector in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
ACOG vs ALEC FAQ
Which is bigger, Alpha Cognition or Alector?
Alector (ALEC) is larger, with a market capitalization of $228.34M compared with $197.31M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or ALEC?
ACOG returned +17.10% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Alector in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Alector is in Health Care.